Scholar Rock Holding Corporation
SRRK
Ранг среди акций
#3510
Scholar Rock Holding Corporation is a biopharmaceutical firm dedicated to... Scholar Rock Holding Corporation is a biopharmaceutical firm dedicated to discovering and advancing treatments for severe medical conditions by targeting the crucial role of protein growth factor signaling. Their lead therapeutic candidate, Apitegromab, an agent designed to inhibit the activation of latent myostatin, has successfully concluded Phase 3 clinical trials for spinal muscular atrophy (SMA). Another key program, SRK-181, is currently undergoing Phase 1 clinical assessment for tackling cancers that exhibit resistance to established checkpoint inhibitor treatments, including anti-PD-1 or anti-PD-L1 antibody therapies. Beyond these, the company cultivates a robust pipeline of innovative potential therapies, aiming to significantly improve the lives of individuals grappling with various severe ailments, such as neurological muscle conditions, malignancies, and fibrotic disorders. In a strategic partnership, Scholar Rock is collaborating with Gilead Sciences, Inc. to identify and develop targeted inhibitors of transforming growth factor beta (TGF-beta) activation, specifically for addressing fibrotic diseases. Established in 2012, Scholar Rock Holding Corporation operates from its headquarters in Cambridge, Massachusetts.
Цена акции
$40.59
Рыночная капитализация
$4.94B
Изменение (1 день)
1.73%
Изменение (1 год)
45.28%
Страна
US
Торговля Scholar Rock Holding Corporation (SRRK)
Категория
Healthcare
EPS для Scholar Rock Holding Corporation (SRRK)
EPS по состоянию на June 2026 TTM: $-3.31
Согласно последним финансовым отчетам и цене акций Scholar Rock Holding Corporation, текущий EPS компании (TTM) составляет $-3.31. В конце 2023 EPS компании составлял $-1.99, меньше, чем показателю 2022 года, равному $-2.21.
История EPS компании Scholar Rock Holding Corporation с 2016 по 2026
EPS на конец каждого года
| Год | EPS | Изменить |
|---|---|---|
| 2026 (TTM) | $-3.31 | 34.01% |
| 2024 | $-2.47 | 24.12% |
| 2023 | $-1.99 | -9.95% |
| 2022 | $-2.21 | -38.44% |
| 2021 | $-3.59 | 29.60% |
| 2020 | $-2.77 | 53.89% |
| 2019 | $-1.80 | -42.86% |
| 2018 | $-3.15 | 125.00% |
| 2017 | $-1.40 | 53.85% |
| 2016 | $-0.91 | 0.00% |
EPS для аналогичных компаний или конкурентов
| Компания | EPS | Разница в EPS | Страна |
|---|---|---|---|
| $17.32 | -623.26% |
US
|
|
| $-7.98 | 141.09% |
US
|
|
| $-5.29 | 59.82% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -938.07% |
NL
|
